Nanobiotix (NASDAQ:NBTX) is a clinical-stage biotechnology company specializing in the development of novel radiotherapy enhancers for oncology applications. Founded in 2003 and headquartered in Paris, France, Nanobiotix’s primary focus is on improving the precision and efficacy of existing radiotherapy treatments. The company’s proprietary technology platform leverages inorganic nanoparticles designed to increase the local dose of radiation absorbed by tumors, potentially enhancing tumor control while sparing surrounding healthy tissue.
The company’s flagship product candidate, NBTXR3, is a first-in-class radioenhancer composed of functionalized hafnium oxide nanoparticles. Administered via a single intratumoral injection prior to standard radiotherapy, NBTXR3 has been studied across several solid tumors, including soft tissue sarcoma, head and neck cancer, prostate cancer and liver metastases. Nanobiotix continues to advance its clinical pipeline through Phase II and Phase III trials, exploring both monotherapy applications and combination regimens with chemotherapy and immuno-oncology agents.
Nanobiotix maintains a global footprint, with offices and research facilities in Europe and the United States. The company’s European headquarters and primary R&D center are located in Paris and Lyon, France, while its U.S. operations are based in New York City and Cambridge, Massachusetts. This transatlantic presence supports collaborative partnerships with leading academic institutions, as well as strategic alliances with pharmaceutical companies to expedite clinical development and regulatory approvals.
Under the leadership of Co‐Founder and Chief Executive Officer Dr. Laurent Levy, Nanobiotix is guided by a management team with extensive experience in oncology drug development, medical device innovation and commercial operations. The company’s board of directors and scientific advisory committee comprise seasoned experts in radiobiology, nanotechnology and clinical oncology. With a commitment to advancing treatment options for cancer patients, Nanobiotix continues to expand its pipeline and seek regulatory clearances across key global markets.
AI Generated. May Contain Errors.
